Free tool
FAERS Monitor: Phyrago
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216099 or its brand name (Phyrago, Dasatinib). Reports on generic versions are filed under their own applications.
Reports
9,294
Serious
8,481
91% of reports
Hospitalization
2,857
Death reported
1,354
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pleural effusion1,211
- drug ineffective728
- drug intolerance575
- drug resistance538
- death470
- diarrhoea441
- thrombocytopenia430
- dyspnoea416
- malignant neoplasm progression399
- fatigue384
- nausea374
- pyrexia373
- off label use367
- hepatotoxicity336
- rash334
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 40 |
| 2007 | 106 |
| 2008 | 113 |
| 2009 | 162 |
| 2010 | 158 |
| 2011 | 94 |
| 2012 | 244 |
| 2013 | 221 |
| 2014 | 372 |
| 2015 | 324 |
| 2016 | 428 |
| 2017 | 538 |
| 2018 | 647 |
| 2019 | 767 |
| 2020 | 706 |
| 2021 | 1,046 |
| 2022 | 541 |
| 2023 | 566 |
| 2024 | 797 |
| 2025 | 821 |
| 2026 | 603 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,865 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug resistanceSignal | 538 | 48.4 | 44.5 | 24,430 |
| pleural effusionSignal | 1,211 | 45.9 | 43.5 | 52,270 |
| hepatotoxicitySignal | 336 | 34.7 | 31.2 | 10,796 |
| drug intoleranceSignal | 575 | 13.5 | 12.5 | 6,659 |
| malignant neoplasm progressionSignal | 399 | 8.8 | 8.0 | 2,772 |
| thrombocytopeniaSignal | 430 | 8.7 | 8.0 | 2,941 |
| pyrexiaSignal | 373 | 2.4 | 2.2 | 321 |
| rash | 334 | 1.7 | 1.6 | 105 |
| dyspnoea | 416 | 1.7 | 1.5 | 112 |
| diarrhoea | 441 | 1.5 | 1.4 | 87 |
| drug ineffective | 728 | 1.3 | 1.2 | 39 |
| death | 470 | 1.2 | 1.1 | 22 |
| fatigue | 384 | 1.1 | 1.0 | 5 |
| nausea | 374 | 1.1 | 1.0 | 2 |
| off label use | 367 | 0.9 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.